Biotech News

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Vaxcyte (PCVX)Vaxcyte2026-01-29 21:07 ESTFinancing

SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering of $500,000,000 of its common stock and pre-funded warrants.

Vaxcyte

Carrier-Sparing Vaccine Platform Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses. Adult VAX-31 Program VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The...

Recent company news

PCVXVaxcyte2026-08-05 20:05 EST

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-07-08 20:05 EST

Vaxcyte to Participate in Upcoming Investor Conferences

PCVXVaxcyte2026-06-02 20:05 EST

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

PCVXVaxcyte2026-05-06 20:05 EST

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-04-07 20:05 EST

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

Stock data

Close: 58.89 USD
Market cap: 6.85B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Related news

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Vaxcyte Announces Pricing of $550 Million Public Offering

GSK announces commencement of tender offer to acquire Nuvalent, Inc.

GSK’s RSV vaccine, Arexvy, receives European approval for expanded use in all adults 18 years and older